Outcome of elexacaftor/tezacaftor/ivacaftor therapy in patients with cystic fibrosis and solid organ transplantation

We report a case series of four patients with cystic fibrosis (CF) and previous solid organ transplantation (SOT) receiving elexacaftor/tezacaftor/ivacaftor therapy for 6 months or more. Data was collected retrospectively. The treatment was well tolerated and all patients reported subjective improve...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric pulmonology 2023-02, Vol.58 (2), p.602-605
Main Authors: Ørum, Matilde B., Rönsholt, Frederikke F., Jeppesen, Majbritt, Bendstrup, Elisabeth, Katzenstein, Terese L., Ott, Peter, Perch, Michael, Pressler, Tacjana, Qvist, Tavs, Jensen‐Fangel, Søren
Format: Article
Language:English
Subjects:
Aminophenols
Benzodioxoles - adverse effects
Case reports
CFTR therapy
Chloride Channel Agonists
Cystic fibrosis
Cystic Fibrosis - drug therapy
Cystic Fibrosis - genetics
Cystic Fibrosis Transmembrane Conductance Regulator - genetics
Cystic Fibrosis Transmembrane Conductance Regulator - therapeutic use
cystic fibrosis transmembrane conductance regulator therapy
Double-Blind Method
Drug Combinations
Drug therapy
ETI
Humans
Mutation
Organ Transplantation
Retrospective Studies
solid organ transplantation
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report a case series of four patients with cystic fibrosis (CF) and previous solid organ transplantation (SOT) receiving elexacaftor/tezacaftor/ivacaftor therapy for 6 months or more. Data was collected retrospectively. The treatment was well tolerated and all patients reported subjective improvements.
ISSN:8755-6863
1099-0496
DOI:10.1002/ppul.26217